Therapeutic Treatment of Resveratrol on Alzheimer’s

Disease with CL2006

Sohrab Vatsia

Need

Figure 1 Figure 2

http://uscnews2.usc.edu/Publication_JPGS/HSCWeekly/2003/HSCW2665p1.jpg

http://www.omh.state.ny.us/omhweb/Statewideplan/2005/images/figure4.2.gif

Alzheimer’s Disease

http://www.nia.nih.gov/NR/rdonlyres/A294D332-71A2-4866-BDD7-A0DF216DAAA4/0/Alzheimers_Disease_Unraveling_the_Mystery.pdf

Figure 1Figure 2

Figure 3

Figure 1

http://www.nia.nih.gov/NR/rdonlyres/A294D332-71A2-4866-BDD7-A0DF216DAAA4/0/Alzheimers_Disease_Unraveling_the_Mystery.pdf

http://www.nia.nih.gov/NR/rdonlyres/A294D332-71A2-4866-BDD7-A0DF216DAAA4/0/Alzheimers_Disease_Unraveling_the_Mystery.pdf

Resveratrol

http://www.resveratrol.org.uk/resveratrol.gif •Rogers, Kara, ed. "Alzheimer's Disease." Encyclopedia Britannica. 15th ed. 2002. 306-07.

Resveratrol’s Role

http://www.chiro.org/nutrition/ABSTRACTS/Resveratrol_in_Prevention_and_Treatment.pdf

CL2006

http://wormsrus.50webs.com/Nematodes/C%20elegans.JPG

Literature Review• Marambaud, 2008

(Marambaud, 2008)

Literature Review

• Vingtdeux, 2005

(O’Neill, 2002)

Literature Review

• Anekonda, 2006

(Rodgers, 2006)

Literature Review

• Duchen, 2004

(Marambaud, 2005)

Hypothesis/ Purpose• The purpose of the experiment is to analyze

the therapeutic and preventative potential of Resveratrol on Alzhemier’s disease.

• Alternate - with the administration of Resveratrol in the CL 2006 model, amyloid-beta production will slow, and the spread of the amyloid-beta molecules will reduce.

• Null - There will be no change in amyloid beta production nor paralysis with the addition of Resveratrol.

Protocols

• Preparation of Bacterial Plates (Siernagle, 2009)

(Yun, 2007)

Protocols

• Resveratrol Administration (Halliwell, 2004)

• Concentration <or = to 100 micromolars

(Lenker, 2001)

Protocols

• C. elegans synchronization• Paralyzed versus Non-Paralyzed

(Cheng,2002)

Protocols

• Staining using Congo Red Dye-registers Amyloid Beta Plaques

(Zhao, 1999)

Do-Ability• This project is do-able because we have all the

necessary materials in the lab• C. elgegans (both CL 2006 and wild-type) are

readily available as well as their environments ie; plates, food, living conditions

• Resveratrol is also readily available, it can be purchased relatively easily

• Amyloid Stain is readily available• Microscope/s are available along with the

prism and a Motic camera are also readily available; thus observation is do-able

Sohrab VatsiaTotal (Tentative) Cost for Project: $767.00Budget Plan 09-10

Mr. Guastella

Sigma-Aldrich Online Catalog

Total $Unit $QuantityProductCat #

$281.50$281.501Resveratrol 500 mgR5010-500MG$267.50$267.501γ-Secretase inhibitor ?90% (TLC), powderS2188-1MG$145.00$145.001Amyloid StainHT60-1KT

Carolina 2009 Catalog

Total $Unit $DescriptionQuantityPageCat #

$73.00$73.00C. elegans culture kit1248NP-17-3525

Special Vendor: University of Minnesota Caenorhabditis Genetic Center

Product

dvIs2[pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4].CL 2006Adult onset paralysis and egg-laying deficiency when raised at 20C

Contact Info

Theresa StiernagleUniversity of MinnesotaDept of GCD6-160 Jackson Hall321 Church Street S.E.Minneapolis, MN 55455phone: 612-625-2265fax: 612-625-4648email: cgc@umn.edu

C. Elegans Control CL 2006 Control C. Elegans adminstered Resveratro l(negative control) CL 2006 Resveratrol (Preventative)

Monitor Lifespan Stain and monitor amyloid levels, as well as monitor lifespan

CL 2006 Resveratrol Therapeutic

Monitor Life Span, Stain, and obeserve amyloid-beta levels

Treat with Resveratrol prior to paralysis. Measure Lifespan, stain,and measure amyloid-beta levels.

Treat on the onset of paralysis. Measure lifespan, stain, and measure amyloid-beta levels

Record Qualitative and Quantitative Data based upon the observations, and following the protocols, (Lifespan, Amyloid-Beta Levels)

CL 2006 Gamma-Secretase

Tested in order to make sure that the amyloid-beta is being targeted (2 or 3 trials)

Statistical Analysis by Two Way Anova followed by Scheffe Post-Hoc (p<.05)

Bibliography• Bundschuh, K. "The worm in humans." 11 Nov. 2008. Biotechnology and Life Sciences in Baden-Württemberg. 6 May 2009

<http://www.bio-pro.de/magazin/wissenschaft/archiv_2008/index.html?lang=en&artikelid=/artikel/00452/index.html>.

• Cheng, Louse. “Compound in Red Wine May Fight Alzeimer’s.” WebMD. 4 Nov. 2005. 15 Apr. 2009 <http://www.webmd.com/alzheimers/news/20051104/compound-in-red-wine-may-fight-alzheimer>.

• Duchen, Michael R. "Roles of Mitochondria in Health and Disease." Whereas some of the genes identified in the control of longevity appear to target mitochondria or at least to alter antioxidant defenses of the cell (Duchen, 2004. 2004. Diabetes. 7 May 2009 <http://diabetes.diabetesjournals.org/cgi/content/full/53/suppl_1/S96>.

• Halliwell, Barry, and John M.C. Gutteridge. Free Radicals in Biology and Medicine. 3rd ed. New York: Oxford UP, 2004.

• Lagouge, Marie, Carmen Argmann, Zachary Gerhart-Hines, Hamid Meziane, Carles Lerin, Frederic Daussin, Nadia Messadeq, Jill Milne, Philip Lambert, Peter Elliott, Bernard Geny, Markku Laakso, Pere Puigserver, and Johan Auwerx. "Resveratrol Improves Mitochondrial Function and Protects Against Metabolic Disease by Activating SIRT1 and PGC-1a." Cell (2006). 20 May 2008.

• Lenker, David P. Professional Guide to Diseases. 8th ed. New York: Williams & Wilkins., 2005• Marambaud, Phillipe. Wine Compound May Help Cut Risk of Alzheimer’s Disease. 16 Nov. • 2005. 24 Apr. 2009 <http://www.sciencedaily.com/releases/2008/06/080617165716.htm>. • McKenzie, Maureen A. "Insulin Receptor-Like Protein." Patent Storm. 5 Oct. 1992. 18 Apr. 2008.

• O,Neill, Bill. "In Methuselah’s Mould." Feature 2 (2004): 0014-017. PLoS Biology. <http://www.culturagalega.org/imaxes/docs/plos_lonxevidade.pdf>.

• "Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease ( whether any of the Company's product ca...)." • Bio-Medicine - latest biology and medical news/technology. 26 June 2007. 29 Apr. 2009 <http://www.bio-medicine.org/medicine-technology/Resveratrol-Studies-Suggest-Broad-

Implications-for-SIRT1-Activation-0Ain-Neurodegenerative-Diseases-of-Aging-Such-as-Alzheimers-Disease-189-3/>.

• Rodgers, Anne B. "Alzheimer's Disease: Unraveling the Mystery." Alzheimer's Disease NIH 2005 (2003).

• Rogers, Kara, ed. "Alzheimer's Disease." Encyclopedia Britannica. 15th ed. 2002. 306-07.

• Society for Neuroscience. "Grape Seed Extract May Reduce Cognitive Decline Associated With Alzheimer's Disease." ScienceDaily 18 June 2008. 29 April 2009 <http://www.sciencedaily.com /releases/2008/06/080617165716.htm>.

• Vingtdeux, Valérie, Ute Dreses-Werringloer, Haitian Zhao, Peter Davies, and Philippe Marambaud. "Therapeutic potential of resveratrol in Alzheimer's disease." BMC Neuroscience 9 (2008): 1-5.